

## Errata Corrige

In the article “Clinical utility of diagnostic markers for malignant pleural mesothelioma” by Grigoriu D.B., *et al. Monaldi Arch Chest Dis* 2009; 71: 1, 31-38; there was a mistake concerning an assay of the C-ERC/mesothelin protein (page 33, first column, second to last paragraph).

**„Antibodies against mesothelin were generated [38, 44, 45] and to date at least two ELISA assays are available, having the brand name of MESOMARK™ by Fujirebio diagnostics (antibodies developed by Scholler *et al* [38]) and one by Immuno-Biological Laboratories under the name of C-ERC/Mesothelin with antibodies developed by Shiomi *et al* [46].**

Should be replaced by:

**„Antibodies against mesothelin were generated [38, 44, 45] and to date at least two ELISA assays are available, having the brand name of MESOMARK™ by Fujirebio diagnostics (antibodies developed by Scholler *et al* [38]) and one yet not available commercially developed by Immuno-Biological Laboratories developed by Segawa *et al* (new ref).**

New Ref: Segawa T, Hagiwara Y, Ishikawa K, Aoki N, Maeda M, Shiomi K, Hino O. MESOMARK kit detects C-ERC/mesothelin, but not SMRP with C-terminus. *Biochemical and Biophysical Research Communications* 2008; 369: 915-918.

We appologize for this mistake.

Editorial Board  
Monaldi Archives for Chest Disease  
Pulmonary Series